Superantigenic activity produced by group A streptococcal isolates is neutralized by plasma from IVIG-treated streptococcal toxic shock syndrome patients.
Norrby-Teglund
A
A
VAMC, Memphis, Tennessee, USA.
Low
D E
DE
McGeer
A
A
Kotb
M
M
D000907:Antibodies, Bacterial / Q000097:blood; D001426:Bacterial Proteins; D005098:Exotoxins / Q000633:toxicity; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D066298:In Vitro Techniques; D007371:Interferon-gamma / Q000096:biosynthesis; D008233:Lymphotoxin-alpha / Q000096:biosynthesis; D008565:Membrane Proteins; D009500:Neutralization Tests; D012772:Shock, Septic / Q000276:immunology* / Q000628:therapy*; D013290:Streptococcal Infections / Q000276:immunology* / Q000628:therapy*; D013297:Streptococcus pyogenes / Q000276:immunology* / Q000302:isolation & purification / Q000472:pathogenicity; D018089:Superantigens / Q000096:biosynthesis*
D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; D005098:Exotoxins; D016756:Immunoglobulins, Intravenous; D008233:Lymphotoxin-alpha; D008565:Membrane Proteins; C117980:SpeA protein, Streptococcus pyogenes; D018089:Superantigens; C027951:erythrogenic toxin; D007371:Interferon-gamma